MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517058872 A) filed by Universitat De Barcelona; Fundacio De Recerca Clinic Barcelona-Institut D'Investigacions Biomediques August Pi I Sunyer; and Hospital Clinic De Barcelona, Barcelona, Spain, on June 19, for 'cd229 and bcma targeting moieties for the treatment of cd229- bcma- positive cancer.'
Inventor(s) include Engel Rocamora, Pablo; Rodriguez Lobato, Luis Gerardo; Fernandez De Larrea Rodriguez, Carlos Jose; and Cardus Granell, Oriol.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a CD229 and a BCMA targeting moiety, wherein the CD229 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD229 and BCMA targeting moiety. Methods of treatment of a CD229-positive cancer, preferably Multiple Myeloma, are also provided."
The patent application was internationally filed on Nov. 10, 2023, under International application No.PCT/EP2023/081453.
Disclaimer: Curated by HT Syndication.
